A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis

[1]  I. Pogribny,et al.  MicroRNAs as biomarkers for clinical studies , 2018, Experimental biology and medicine.

[2]  H. Cao,et al.  miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1 , 2017, World journal of gastroenterology.

[3]  A. Masotti,et al.  Circulating microRNAs and Bioinformatics Tools to Discover Novel Diagnostic Biomarkers of Pediatric Diseases , 2017, Genes.

[4]  H. Cortez‐Pinto,et al.  miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice , 2017, Cell Death & Disease.

[5]  P. Bedossa,et al.  Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis , 2017 .

[6]  P. Bhuyan,et al.  Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience. , 2016, Journal of clinical and experimental hepatology.

[7]  A. Pulvirenti,et al.  Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[8]  K. Yoshizato,et al.  MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Masayuki Kanki,et al.  MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. , 2016, Toxicology letters.

[10]  Jianguo Xia,et al.  Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis , 2016, Current protocols in bioinformatics.

[11]  M. Ji,et al.  Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT. , 2016, Clinical science.

[12]  Guang Bai,et al.  MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1. , 2016, Life sciences.

[13]  T. Luedde,et al.  Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. , 2016, Clinical science.

[14]  H. Fallatah,et al.  Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease , 2016, Hepatitis monthly.

[15]  Z. Zong,et al.  MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α , 2016, Molecular Cancer.

[16]  J. DiStefano,et al.  Circulating microRNAs in nonalcoholic fatty liver disease , 2016, Expert Review of Gastroenterology & Hepatology.

[17]  H. Bian,et al.  The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women , 2016, Journal of Translational Medicine.

[18]  J. Deiuliis.  MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics , 2015, International Journal of Obesity.

[19]  C. Hammer,et al.  Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis , 2015, PloS one.

[20]  V. Paradis,et al.  Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression , 2015, Gut.

[21]  K. Kodys,et al.  Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis , 2015, Journal of Translational Medicine.

[22]  Matthew K. Knabel,et al.  Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice , 2015, PloS one.

[23]  T. Luedde,et al.  Elevated miR‐122 serum levels are an independent marker of liver injury in inflammatory diseases , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[24]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[25]  A. Wree,et al.  Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease , 2014, PloS one.

[26]  T. Luedde,et al.  Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. , 2014, Journal of hepatology.

[27]  Munis Dundar,et al.  Circulating microRNAs in patients with non-alcoholic fatty liver disease. , 2014, World journal of hepatology.

[28]  A. Sanyal,et al.  Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis , 2014, Gut.

[29]  Anthony D. Schmitt,et al.  Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma , 2014, Hepatology.

[30]  Soumitra S Ghosh,et al.  Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[31]  Hiroya Yamada,et al.  Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[32]  Tao-Tao Liu,et al.  Circulating microRNAs as a Fingerprint for Liver Cirrhosis , 2013, PloS one.

[33]  Jun Wei,et al.  MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[34]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[35]  A. Näär,et al.  MicroRNAs in metabolism and metabolic disorders , 2012, Nature Reviews Molecular Cell Biology.

[36]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[37]  Chi-Ying F. Huang,et al.  miRTarBase: a database curates experimentally validated microRNA–target interactions , 2010, Nucleic Acids Res..

[38]  B. Neuschwander‐Tetri,et al.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease , 2010, Hepatology.

[39]  N. Rajewsky,et al.  The evolution of gene regulation by transcription factors and microRNAs , 2007, Nature Reviews Genetics.

[40]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[41]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[42]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.